Up to 40 percent of patients suffering from lung cancer do not respond to a targeted therapy designed to block tumor growth - a puzzling clinical setback that researchers have long tried to solve.
Now, scientists at Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute have discovered why that intrinsic resistance occurs - and they pinpoint a drug they say could potentially reverse it.
Their findings, published in the iJournal of Clinical Investigation/i, ...
Up to 40 percent of patients suffering from lung cancer do not respond to a targeted therapy designed to block tumor growth - a puzzling clinical setback that researchers have long tried to solve.
Now, scientists at Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute have discovered why that intrinsic resistance occurs - and they pinpoint a drug they say could potentially reverse it.
Their findings, published in the iJournal of Clinical Investigation/i, ...